SCHEMBL4370352

SCHEMBL4370352

COc1cccnc1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29413198 1.00
Formaldehyde SCHEMBL28255709 0.94 PLAU (0.43)
Formic Acid Methyl Ester SCHEMBL27958845 0.89 NFE2L2 (0.43)
Formic Acid SCHEMBL27958614 0.89 PLAU (0.44)
SCHEMBL13330989 0.81 PDE10A (0.42)
SCHEMBL2370946 0.79 CHRNB2 (0.47)
SCHEMBL29612256 0.79 CHRNB4 (0.49)
SCHEMBL63365 0.79 CHRNB4 (0.49)
SCHEMBL18833817 0.78 CHRNB2 (0.49)
Hydrochloric Acid SCHEMBL5669854 0.77 CHRNB4 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114361590-B Electrolyte additive for lithium ion battery, electrolyte and lithium ion battery 松山湖材料实验室 2023-07-25 CN claimed
CN-114361590-A Lithium ion battery electrolyte additive, electrolyte and lithium ion battery 松山湖材料实验室 2022-04-15 CN claimed
CN-122080069-A Phospholipid compounds and uses thereof 2026-05-26 CN disclosed
US-12612414-B2 Nitrile SUMO inhibitors and uses thereof CIT THERAPEUTICS, INC. (US) 2026-04-28 US disclosed
US-12473314-B2 Phospholipid compounds and uses thereof GILEAD SCIENCES, INC. (US) 2025-11-18 US disclosed
US-20250304549-A1 HYDROXYAMIDE DERIVATIVE AND USE THEREOF SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) 2025-10-02 US disclosed
EP-4615832-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS Bristol-Myers Squibb Company (US) 2025-09-17 EP disclosed
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 US disclosed
WO-2025137483-A1 RHO-ASSOCIATED PROTEIN KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2025-06-26 WO disclosed
CN-120152968-A Substituted heterocyclic compounds 百时美施贵宝公司 2025-06-13 CN disclosed
US-20250163078-A1 IMIDAZOPYRIDAZINE DERIVATIVE, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2025-05-22 US disclosed
CN-104428299-A 5-azaindazole compounds and methods of use HOFFMANN LA ROCHE 2015-03-18 CN disclosed
EP-2827857-A1 SPIROCYCLIC DIHYDRO-THIAZINE AND DIHYDRO-OXAZINE BACE INHIBITORS, AND COMPOSITIONS AND USES THEREOF Elan Pharmaceuticals Inc. (US) 2015-01-28 EP disclosed
WO-2014121040-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-08-07 WO disclosed
US-20140221310-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (US) 2014-08-07 US disclosed
WO-2014066196-A1 2-PYRIDYLOXY-3-SUBSTITUTED-4-NITRILE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2014-05-01 WO disclosed
WO-2014066196-A1 2-PYRIDYLOXY-3-SUBSTITUTED-4-NITRILE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2014-05-01 WO disclosed
WO-2013142613-A1 SPIROCYCLIC DIHYDRO-THIAZINE AND DIHYDRO-OXAZINE BACE INHIBITORS, AND COMPOSITIONS AND USES THEREOF ELAN PHARMACEUTICALS, INC. (US) 2013-09-26 WO disclosed
WO-2009103950-A1 FLUORINATED PYRIDIN-4-0NES BTG INTERNATIONAL LIMITED (GB) 2009-08-27 WO disclosed
WO-2009103950-A1 FLUORINATED PYRIDIN-4-0NES BTG INTERNATIONAL LIMITED (GB) 2009-08-27 WO disclosed